Table 1.
Clinical and biochemical characteristics of study population.
Fig 1.
Serum levels of CTRP9 in control, CAD, T2DM and CAD+T2DM category.
a) Serum CTRP9 levels were lower in controls (148.7 ± 4.0) than CAD (202.0 ± 4.9), T2DM (191.4 ± 10.1) and CAD+T2DM (211.2 ± 6.8). (all, p<0.001). b) Serum concentration of CTRP9 was higher in women (208.8 ± 6.2) compared to men (181.8 ± 3.7) (p<0.001).
Table 2.
Odds ratios for development of CAD, T2DM and CAD+T2DM based on serumCTRP9 levels.
Fig 2.
Circulating levels of adiponectin, inflammatory cytokines and soluble adhesion molecules in control, CAD, T2DM and CAD+T2DM category.
a) A higher levels of serum adiponectin was demonstrated in controls compared to persons with CAD and CAD+T2DM (both, p<0.001). b) Serum concentration of IL-6 was higher in patients groups compared to controls (all, p<0.001). c) TNF-α concentration were higher in CAD, T2DM and CAD+T2DM category compared to control (all, p<0.001). d) Those with CAD, T2DM, and CAD+T2DM showed a higher serum levels of E-selectin compared to control group (all, p<0.001). e) sICAM-1 was higher in case groups compared to control (all, p<0.01). Also, higher serum levels of sICAM-1 were shown in CAD (p<0.05) and CAD+T2DM patients (p<0.01) compared to T2DM group. f) Serum level of sVCAM-1 had higher levels in patients compared to healthy individuals (all, p<0.001).
Table 3.
Pearson correlation of CTRP9 with anthropometric and metabolic parameters.